SKU(재고 관리 코드):MAC615Hu22
Monoclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
Monoclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
Product No.
MAC615Hu22
Organism Species
Homo sapiens (Human).
Source
Monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
n/a
Ig Isotype
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
n/a
Buffer Formulation
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Traits
Liquid
Concentration
1mg/mL
Organism Species More
n/a
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against MCL1. It has been selected for its ability to recognize MCL1 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
Magazine |
Citations |
Cancers |
Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075 |
ACTA NEUROPATHOLOGICA COMMUNICATIONS |
Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma Pubmed: 32410663 |
Cancers (Basel) |
BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760 |
Catalog No. |
Related products for research use of Homo sapiens (Human) Organism species |
Applications (RESEARCH USE ONLY!) |
RPC615Hu01 |
Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) |
Positive Control; Immunogen; SDS-PAGE; WB. |
PAC615Hu01 |
Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) |
WB; IHC; ICC; IP. |
FAC615Hu01 |
Anti-Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Polyclonal Antibody |
Flow cytometry. |
MAC615Hu22 |
Monoclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) |
WB; IHC; ICC; IP. |
SEC615Hu |
ELISA Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) |
Enzyme-linked immunosorbent assay for Antigen Detection. |
LMC615Hu |
Magnetic Luminex Assay for Antigen Detection. |